Macrilen Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6861409 NOVO Growth hormone secretagogues
Aug, 2022

(1 year, 11 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Oct, 2027

(3 years from now)

Macrilen is a drug owned by Novo Nordisk Inc. It is used for diagnosing adult growth hormone deficiency. Macrilen uses Macimorelin Acetate as an active ingredient. Macrilen was launched by Novo in 2017. It is is available in for solution form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 12, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2022
Orphan Drug Exclusivity(ODE-170) Dec 20, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MACIMORELIN ACETATE ingredient

NCE-1 date: 20 December, 2021

Market Authorisation Date: 20 December, 2017

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin


More Information on Dosage

MACRILEN family patents

Family Patents